Trial Profile
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 31 May 2023 Status changed from active, no longer recruiting to completed.
- 04 May 2023 Planned End Date changed from 1 Apr 2023 to 1 May 2023.
- 05 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Apr 2023.